GPX4 and ovarian carcinoma: Indeed, our latest publication revealed that MAP30, one of the bioactive constituents in bitter melon extract (BME), decreased ATP production in OCM-cocultured ovarian cancer cells and reduced the GSH/GSSG ratio and GPX4 expression similar to Erastin in a dose-dependent manner, which inversely correlated with the escalated cellular ROS and lipid peroxidation levels in ovarian cancer cells through AMPK signaling [36].